NCT04559425 Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
| NCT ID | NCT04559425 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hospital for Sick Children |
| Condition | Heart Block Complete |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2020-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharmaceuticals administered via the mother. To this day, physicians need to make decisions about the management of such pregnancies without evidence from prospective clinical trials on drug efficacy and safety. The SLOW HEART REGISTRY is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated heart block to the best of care. The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.
Eligibility Criteria
Inclusion Criteria: * Written informed maternal consent to participate in the Slow Heart Registry * High-degree (2nd; 2:1; 2nd-3rd or 3rd degree) AVB diagnosed ≤ 32+0 weeks with or without hydrops * Enrollment within maximally 8 days of high-degree AVB diagnosis * Positive or pending anti-Ro/La antibody test results at the time of enrollment Exclusion Criteria: * AVB associated with major CHD (e.g. left atrial isomerism, cc-TGA) * AVB with known negative anti-Ro and/or La antibody test result at enrollment * 1st degree AVB * Sinus bradycardia with normal 1:1 AV conduction * Blocked atrial bigeminy (irregular atrial rate with failure of AV conduction of the premature atrial beat) * Primary delivery for postnatal treatment * Maternal-fetal conditions (other than cardiac NL) associated with high odds of premature delivery or death (e.g. renal failure, significant infectious diseases, major extracardiac anomalies, PROM, etc.) * Preexisting maternal mental disorder (e.g. bipolar, mania, severe depression, substance abuse) * Poorly controlled insulin-dependent diabetes (HbA1c \>7%) at CAVB diagnosis * Oligohydramnios (deepest/maximal vertical pocket \<2 cm) * Severe IUGR (estimated fetal weight \<3rd percentile)
Contact & Investigator
Edgar Jaeggi, MD
PRINCIPAL INVESTIGATOR
The Hospital for Sick Children, Toronto
Frequently Asked Questions
Who can join the NCT04559425 clinical trial?
This trial is open to female participants only, aged 16 Years or older, up to 50 Years, studying Heart Block Complete. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04559425 currently recruiting?
Yes, NCT04559425 is actively recruiting participants. Contact the research team at slow.heart@sickkids.ca for enrollment information.
Where is the NCT04559425 trial being conducted?
This trial is being conducted at Phoenix, United States, San Francisco, United States, Denver, United States, Washington D.C., United States and 11 additional locations.
Who is sponsoring the NCT04559425 clinical trial?
NCT04559425 is sponsored by The Hospital for Sick Children. The principal investigator is Edgar Jaeggi, MD at The Hospital for Sick Children, Toronto. The trial plans to enroll 350 participants.